Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.63 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.63 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253115 | 0.89 | PRSS12 (0.67) | PTPN7PTPN12PTPN22RAB9AALDH1A1 | |
| SCHEMBL4250099 | 0.88 | MAPT (0.70) | PTPN7PTPN12PTPN22RAB9AKDM4E | |
| SCHEMBL4918623 | 0.82 | PTPN7 (0.77) | PTPN7PTPN12PTPN22RAB9AKDM4E | |
| SCHEMBL17916672 | 0.82 | PTPN7 (0.67) | PTPN7PTPN12PTPN22RAB9AKDM4E | |
| SCHEMBL14315172 | 0.75 | MAPT (1.00) | RAB9AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL5935569 | 0.74 | MAPT (0.79) | RAB9AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL16562055 | 0.73 | F10 (0.71) | RAB9AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL10872798 | 0.73 | RAB9A (0.63) | PTPN22RAB9AKDM4EALDH1A1POLB | |
| SCHEMBL11279344 | 0.73 | DYRK1A (1.00) | RAB9ASMN1; SMN2CASP3SENP8DYRK1A | |
| SCHEMBL4252877 | 0.73 | RAB9A (0.61) | RAB9AKDM4EALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | claimed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | CERS2, CHKB, SPHK2 | PTPN7 2659/4885PTPN12 2674/4885PTPN22 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.